Merck Betting Up To $1B On Endocyte's Cancer Treatment
Under the pact, Endocyte will land $120 million upfront and be eligible for milestone payments of up to $880 million based on goals for six cancer indications, the companies said. If vintafolide is cleared for sale, domestic profits will be split equally and Endocyte will receive double-digit royalties from foreign sales.
“We think this is a transformative deal for...
To view the full article, register now.